Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease
暂无分享,去创建一个
L. Ijlst | W. Kulik | F. Wijburg | H. V. Lenthe | J. Ruijter | T. Wagemans | N. V. Vlies
[1] R. Steiner,et al. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP) , 2013, Journal of Inherited Metabolic Disease.
[2] G. Węgrzyn,et al. Changes in hair morphology as a biomarker in gene expression-targeted isoflavone therapy for Sanfilippo disease. , 2012, Gene.
[3] A. Węgrzyn. Gene expression‐targeted isoflavone therapy , 2012, IUBMB life.
[4] S. Stockler,et al. Longitudinal observations of serum heparin cofactor II-thrombin complex in treated Mucopolysaccharidosis I and II patients , 2012, Journal of Inherited Metabolic Disease.
[5] G. Węgrzyn,et al. Genistein in Sanfilippo disease: A randomized controlled crossover trial , 2012, Annals of neurology.
[6] T. Braulke,et al. Residual activity and proteasomal degradation of p.Ser298Pro sulfamidase identified in patients with a mild clinical phenotype of Sanfilippo A syndrome , 2011, American journal of medical genetics. Part A.
[7] M. O'Callaghan,et al. Genistein supplementation in patients affected by Sanfilippo disease , 2011, Journal of Inherited Metabolic Disease.
[8] E. Glamuzina,et al. Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points , 2011, Journal of Inherited Metabolic Disease.
[9] S. Raoul,et al. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[10] D. Zafeiriou,et al. Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece , 2011, American journal of medical genetics. Part A.
[11] J. Petty,et al. Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases , 2010, Journal of Inherited Metabolic Disease.
[12] R. Wevers,et al. Mucopolysaccharidosis type IIIA: Clinical spectrum and genotype‐phenotype correlations , 2010, Annals of neurology.
[13] M. Elleder,et al. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations , 2010, Journal of Inherited Metabolic Disease.
[14] H. Omran,et al. Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations b , 2010, Human mutation.
[15] Carmela Di Domenico,et al. Serum MIP-1 α level: a biomarker for the follow-up of lentiviral therapy in mucopolysaccharidosis IIIB mice , 2010, Journal of Inherited Metabolic Disease.
[16] H. Azzouz,et al. Incidence of mucopolysaccharidoses in Tunisia. , 2009, La Tunisie medicale.
[17] A. Pshezhetsky,et al. Sanfilippo syndrome type C: mutation spectrum in the heparan sulfate acetyl‐CoA: α‐glucosaminide N‐acetyltransferase (HGSNAT) gene , 2009, Human mutation.
[18] L. Kudo,et al. Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy , 2009, Proceedings of the National Academy of Sciences.
[19] G. Węgrzyn,et al. Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients. , 2008, Current therapeutic research, clinical and experimental.
[20] A. Pshezhetsky,et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. , 2008, Molecular genetics and metabolism.
[21] J. Hopwood,et al. Functional analysis of the HGSNAT gene in patients with mucopolysaccharidosis IIIC (Sanfilippo C Syndrome) , 2007, Human mutation.
[22] S. McCandless,et al. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). , 2007, Molecular genetics and metabolism.
[23] J. Wittes,et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. , 2006, The Journal of pediatrics.
[24] F. Krummenauer,et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany , 2005, Journal of Inherited Metabolic Disease.
[25] N. Cengiz,et al. Glycosaminoglycans in childhood urinary tract infections , 2005, Pediatric Nephrology.
[26] J. E. Wraith,et al. The first 5years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I , 2005, Expert opinion on pharmacotherapy.
[27] Joseph Muenzer,et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). , 2004, The Journal of pediatrics.
[28] O. Amaral,et al. Prevalence of lysosomal storage diseases in Portugal , 2004, European Journal of Human Genetics.
[29] J. Hopwood,et al. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications , 2001, Human mutation.
[30] J. Hopwood,et al. Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients. , 2001, Molecular genetics and metabolism.
[31] R. A. Wevers,et al. The frequency of lysosomal storage diseases in The Netherlands , 1999, Human Genetics.
[32] P. Meikle,et al. Prevalence of lysosomal storage disorders. , 1999, JAMA.
[33] R. Wevers,et al. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. , 1992, Clinical chemistry.
[34] R. Wevers,et al. Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. , 1989, Clinical chemistry.
[35] T. Perniola,et al. Recurrent comatose state with red urine in a female infant , 1982, Journal of Inherited Metabolic Disease.
[36] K. Figura,et al. Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C) , 1981, Clinical genetics.
[37] C. Epstein,et al. Lack of relationship between blood and urine levels of glycosaminoglycans and lysomal enzymes. , 1975, Biochemical medicine.
[38] K. Meyer,et al. THE FATE OF INJECTED MUCOPOLYSACCHARIDES , 1962 .
[39] R. Wevers,et al. UvA-DARE ( Digital Academic Repository ) Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype , 2017 .
[40] G. Węgrzyn,et al. The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients. , 2012, JIMD reports.
[41] J. Hopwood. Sanfilippo Syndrome: Clinical Genetic Diagnosis and Therapies , 2007 .
[42] J. Hopwood,et al. Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes , 1999, European Journal of Human Genetics.
[43] K. Meyer,et al. The fate of injected mucopolysac-charides. , 1962, The Journal of clinical investigation.